Gain Therapeutics, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. This unaudited filing covers the three months ended March 31, 2023. Gain Therapeutics is a pre-revenue biotechnology company developing small-molecule therapeutics using its licensed SEE-Tx platform. Its programs remain preclinical; it has not generated product sales.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $55,180 | $45,006; increase of $10,174 |
| Research and development expense | $2.79 million | $1.56 million; increase of $1.23 million |
| General and administrative expense | $2.49 million | $1.78 million; increase of $717,000 |
| Total operating expenses | $5.28 million | $3.33 million |
| Operating loss | $5.23 million | $3.29 million |
| Net loss | $5.14 million | $3.27 million |
| Net loss per share, basic and diluted | $0.43 | $0.28 |
| Cash used in operating activities | $4.22 million | $2.45 million |
Revenue was principally collaboration revenue; no product revenue was reported. Profitability and product margins are not meaningful measures at this pre-commercial stage. Management attributed higher R&D expense mainly to third-party work on Parkinson’s and Gaucher disease programs. Higher G&A reflected increased legal and professional fees, D&O insurance, headcount and stock-based compensation.
- Liquidity: At March 31, cash and cash equivalents were $5.99 million and marketable securities were $12.82 million, totaling $18.8 million. Total current assets were $19.32 million and current liabilities $5.15 million.
- Cash flow: Investing activities provided $2.11 million, principally from Treasury security maturities, partly offset by purchases. Financing activities provided $749,000, mainly ATM proceeds. Cash, cash equivalents and restricted cash ended the quarter at $6.02 million.
- Debt and other obligations: Loan balances totaled approximately $588,000, including $109,000 current. Operating lease liabilities totaled approximately $618,000. Research commitments for 2023 were $3.2 million.
- Equity financing: The ATM offering raised net proceeds of approximately $771,000 from 203,774 shares sold at an average $4.48 per share. Approximately $15 million of ATM capacity remained at quarter-end. Shares outstanding were 12,087,142 at March 31, versus 11,883,368 at year-end.
Material changes and outlook
- Compared with Q1 2022, operating expenses rose by $1.95 million and net loss increased by $1.86 million. Operating cash use also increased by $1.77 million.
- Management estimated existing cash, cash equivalents and marketable securities would fund operating and capital expenditure needs into the third quarter of 2024. The estimate depends on assumptions that could prove incorrect; the company expects to need additional financing.
- Management said it completed IND-enabling toxicology studies for GT-02287, its GBA1 Parkinson’s disease candidate, and expected to submit the regulatory package for a Phase 1 study in Australia in the second half of 2023. The planned study would assess safety and pharmacokinetics in healthy volunteers. The candidate had not entered clinical trials as of the filing.
- The company said it was prioritizing Parkinson’s and Gaucher disease programs, continuing work on Krabbe disease and alpha-1 antitrypsin deficiency, and pursuing oncology programs and potential partnerships. It described efforts to streamline operations and improve capital efficiency.
- Subsequent developments disclosed in the filing include a March-announced €1.2 million grant for the alpha-1 antitrypsin deficiency program and a May-announced CHF 2.5 million Innosuisse grant for the Parkinson’s program. The latter was announced after quarter-end; related research activities were expected to start in Q2.
- The Zentalis collaboration had concluded. Management cited financing-market volatility, inflation, rising interest rates, bank liquidity concerns, foreign-exchange movements and supply-chain disruption as risks to financing and operations. Additional equity financing may dilute stockholders, while collaboration or licensing arrangements could require concessions of rights.
- Available-for-sale U.S. Treasury securities had $52,035 of unrealized losses at March 31, attributed primarily to interest-rate changes; the company recorded no credit-loss allowance. No material legal proceedings were reported. Management concluded disclosure controls were effective as of March 31, 2023.
Key investor verification points
- Track whether the GT-02287 regulatory submission and Phase 1 trial proceed on the stated timetable, and review the resulting clinical data; current evidence described in the filing is preclinical.
- Assess the cash-runway estimate against ongoing operating cash use, the $3.2 million research commitment and potential changes in development spending.
- Verify the grant amounts, conditions, timing and cash availability, particularly for the post-quarter May award.
- Monitor future ATM or other financing activity, remaining capacity, share issuance and resulting dilution.
- Evaluate whether partnerships or other financing are secured on acceptable terms, given the company’s lack of product revenue and expected continuing losses.